Articles tagged with Brain Tumors
Researchers developed a novel combination therapy that eradicates tumors in select patients, with prolonged survival rates. The therapy has shown promise in treating glioblastoma, a notoriously difficult-to-treat primary brain cancer.
Research reveals that brain tumor cells communicate with astrocytes through microtubes, transferring mitochondria to enhance growth. This connection increases treatment resistance and tumorigenicity in glioblastoma tumors.
Glioblastoma steals cognitive faculties as it spreads, but its insidious ability to infiltrate neighboring networks may be its undoing. Researchers found neural activity can restructure connections in surrounding tissue, causing decline. The drug gabapentin blocks this growth-causing activity in mice with glioblastoma.
Brain cancer cells use mitochondria from healthy astrocytes to boost energy production and amplify cancer stem cells, making glioblastoma more deadly and difficult to treat. Researchers discovered that acquiring mitochondria is a common process in glioblastoma, with implications for developing new treatments.
A multi-institutional phase 3 clinical trial found that a cancer stem cell test can accurately decide more effective treatments and lead to increased survival for patients with recurrent glioblastoma. ChemoID, a CLIA-accredited diagnostic test, was used to select chemotherapy treatments, resulting in significantly lower risk of death a...
Three high school students co-authored a paper using AI engine PandaOmics to discover new therapeutic targets for glioblastoma multiforme, a common and aggressive malignant brain tumor. The study identified three genes strongly correlated with both aging and glioblastoma as potential therapeutic targets.
Scientists successfully opened the blood-brain barrier using a novel ultrasound device, delivering chemotherapy to treat glioblastoma patients. The treatment increased drug concentrations by 4-6 times and was safe and well-tolerated.
Researchers identified three novel dual-purpose therapeutic targets using PandaOmics, which could treat both aging and glioblastoma multiforme. The target hypotheses include cyclic nucleotide gated channel subunit alpha 3 (CNGA3), glutamate dehydrogenase 1 (GLUD1) and sirtuin 1 (SIRT1).
A new study by St. Jude Children's Research Hospital found that children with supportive environments fared better than those living in neighborhoods with economic hardship. Higher EHI scores were associated with lower cognitive abilities and greater decline after treatment, especially in math skills.
Neurologist Soma Sengupta introduces the concept of integrative neuro-oncology, combining conventional treatments with alternative therapies to enhance patient well-being. Her approach prioritizes the unique needs of brain tumor patients and their caregivers, promoting a holistic understanding of medicine.
Scientists have created a detailed map of human spinal cord cell formation, shedding light on how injuries and diseases arise. The study's findings hold promise for developing new therapies for spinal cord injuries and diseases like ALS.
Researchers at Sanford Burnham Prebys have discovered that a 3D view of the genome can reveal genes in tumors that may be future targets for therapy. By visualizing how the genome is organized and arranged within tumor cells, they were able to identify new candidate targets for treatments.
A study of 7807 children found no increased risk of brain tumours, leukemia, or lymphoma after a single CT scan. However, exposure to 4 or more scans before adulthood significantly increases the risk of intracranial tumours, leukemia, and non-Hodgkin lymphoma
A novel gel has cured 100% of mice with aggressive brain cancer, a breakthrough that could lead to new treatments for glioblastoma. The gel combines an anticancer drug and antibody to target tumor cells and stimulate the immune system.
A team of researchers has discovered that a naturally produced chemical in the body helps glioblastoma cells go unrecognized by the immune system. The findings could lead to the development of new and more effective treatments for this aggressive brain cancer.
Researchers at Duke University have successfully improved the resolution of Magnetic Resonance Imaging (MRI), capturing images of a mouse brain with unprecedented sharpness. The breakthrough allows for the visualization of microscopic details within the brain, enabling new insights into neurodegenerative diseases such as Alzheimer's an...
Researchers at Cold Spring Harbor Laboratory have developed a potential therapeutic for diffuse intrinsic pontine glioma (DIPG) using antisense oligonucleotide technology. The treatment has slowed tumor growth, reversed changes in cancer cells, and increased survival rates in mice with DIPG.
Researchers develop mechanical nanosurgery to destroy tumour cells from within, reducing GBM tumour size universally, including in TMZ-resistant cases. The treatment uses magnetically controlled carbon nanotubes to provide mechanical stimulation, damaging cellular structures and causing tumour cell death.
Researchers used long-read sequencing to identify novel mutational patterns and complex genomic rearrangements in cancer genomes, including those associated with liposarcoma. This approach offers a more comprehensive understanding of DNA mutations and their impact on cell function.
Researchers have developed a new technique that combines real-time images with short-wave infrared light to differentiate between cancerous tumours and healthy tissue. This innovation has the potential to improve treatment outcomes for neuroblastoma patients by allowing surgeons to remove cancerous cells more precisely.
Researchers at Massachusetts General Hospital found that normalizing glioblastoma blood vessels using an antibody against VEGF improves the infiltration of CAR-T cells into tumors in mice, inhibiting tumor growth and prolonging survival. This approach may also improve CAR-T therapy against other solid tumors.
Researchers have discovered that high-grade glioma brain tumors have LDL receptors, which could be targeted by drugs already in development. The study's findings pave the way for using nanoparticle-based therapies to starve the tumors of energy and cause disruptions to their growth and spread.
Two compounds, A5 and C1, have shown promising results in inhibiting the growth of glioblastoma cells, a type of aggressive brain cancer. Further research is needed to confirm their effectiveness on normal nerve cells and to move towards clinical trials.
Researchers have identified a key cause of metastasis from aggressive brain cancer in children and found a potential new therapy. Medulloblastoma cells hijack neurodevelopmental signaling pathways to promote tumor cell spreading. Targeting these pathways with a drug called dasatinib has shown promise in killing metastatic tumors.
Researchers created a novel approach to deliver anti-cancer drugs directly to brain tumor sites in children, targeting specific locations while sparing normal brain regions. This targeted delivery method enhances the efficacy of existing treatments and reduces adverse side effects.
A new approach using nanoparticles has been shown to transport drugs across the blood-brain barrier in mice with medulloblastoma. The nanoparticles target a protein called P-selectin, which binds naturally to cancer cells, and trigger transcytosis to deliver drugs to brain tissue.
Researchers from UCL Cancer Institute found that head injuries may contribute to the development of gliomas, a type of aggressive brain tumour. Studies in mice and human populations suggest that genetic mutations acting with inflammation can change cell behavior, increasing cancer risk.
Glioblastoma patients have a median survival time of 15 months due to the rapid infiltration of brain tissue. Cellular senescence, previously thought to be only a marker of aging, is now linked to cancer progression, with senescent cells promoting tumor growth and immune evasion.
Researchers discovered a new approach to treating ependymoma, a rare childhood brain tumor, by targeting YAP fusion proteins. The study found that blocking the function of BRD4 gene expression regulator can prevent tumors from forming.
Researchers at Massachusetts General Hospital found that losartan can reduce the expression of inflammatory enzymes responsible for immunotherapy-related edema. The study suggests that losartan may allow patients to continue receiving immune checkpoint inhibitors without developing adverse effects in the brain.
Researchers developed a new device to identify key membrane proteins in urine indicative of brain tumors. This could lead to early detection and increased survival rates for patients.
Researchers developed a translational step forward in treating brain tumors using intraventricular immunovirotherapy, which has shown safety and efficacy in recent clinical trials. This approach uses oncolytic herpes simplex virus type-1 to target high-grade glioma with promising results.
Researchers from UTSA and UT Health San Antonio are developing compounds that target the estrogen receptor-beta, which suppresses cancer growth. The goal is to identify a novel ER-beta agonist with potential as a therapeutic strategy for treating GBM in patients.
Researchers at Michigan Medicine discovered a gene, ZMYND8, that contributes to the survival of mutant IDH1 glioma cells in response to radiation. Knocking out ZMYND8 renders the cells radiosensitive, offering a new therapeutic avenue for patients.
A new study led by Massachusetts General Hospital researchers reveals that an investigational drug called YTX-7739 can delay the growth of brain tumors and increase their sensitivity to conventional chemotherapy. The drug works by inhibiting de novo lipid synthesis, a process used by cancer cells for energy production.
Researchers are launching a clinical trial testing azeliragon, a RAGE inhibitor, with chemoradiotherapy to re-sensitize brain tumours that resist radiotherapy. The trial aims to predict radioresistance in brain metastasis using liquid biopsy.
A team of researchers from Korea and USA identified the importance of lipid homeostasis in overcoming brain cancer radioresistance. They found that regulating diacylglycerol kinase B and diacylglycerol acyltransferase 1 could potentially sensitize brain cancer cells to radiotherapy, offering a new treatment strategy.
A computational model predicts brain tumour growth using MRI data, providing valuable insights for clinicians. The study uses anonymous patient data to develop a predictive model for glioblastoma multiforme (GBM) growth, which can be used to inform treatment decisions.
Researchers discovered a drug combination that targets immune evasion pathways in MYC amplified Medulloblastoma, a fatal childhood brain cancer. The treatment uses epigenetic drugs to unblock 'don't eat me' pathways and make tumors more appealing to macrophages.
A new study has mapped the parts of the brain that support fluid intelligence, a key feature of human cognition. The research found that patients with damage to the right frontal regions performed poorly in tasks requiring problem-solving and reasoning.
A team of researchers from Cold Spring Harbor Laboratory has made a breakthrough in understanding the deadly brain cancer glioblastoma. By linking the BRD8 protein to another key protein, P53, they have identified a potential target for new treatments that could extend patient survival and improve outcomes.
UCSF researchers identified glioma's cellular source of recurrent disease, finding cells shift to mesenchymal, radiation-resistant phenotype in response to standard therapy. Paracrine signals from tumor microenvironment drive this transition through AP1 pathway, leading to therapy resistance and tumor recurrence.
Researchers found that Black patients were more likely to be recommended against surgical removal of their brain tumors, regardless of tumor size or socioeconomic status. The study provides a basis for future research on racial bias in clinical decision-making and its impact on patient outcomes.
Researchers have identified three new subtypes of glioblastoma, a type of brain cancer, based on the presence of specific non-cancer cells. These subtypes may help identify targeted therapies, such as immunotherapies, for improved patient outcomes.
A massive collaborative study using federated learning developed a model that enhances identification and prediction of boundaries in three tumor sub-compartments without compromising patient privacy. The dataset, comprising 6,314 glioblastoma patients from 71 sites globally, is the largest and most diverse ever considered.
Scientists have developed a detailed 'atlas' of human fetal brain development, revealing the origin of aggressive medulloblastomas. The study identifies a collection of progenitor cells that give rise to these tumors and provides potential targets for therapy.
A study published in Trends in Cancer suggests that targeting vulnerabilities in glioblastoma cancer cells, which maintain resemblance to the cells of origin, may lead to effective therapies. The research aims to identify ways to block these identity shifts and develop personalized treatments.
A study by HSE researchers found that only the left inferior frontal gyrus is critically involved in action naming, which could help preserve speech in patients after brain surgery. The study used fMRI and rTMS to stimulate the brain and found that stimulating this region led to more accurate action naming.
Kevin McHugh, a Rice bioengineer, has received the Distinguished Scientist Award from The Sontag Foundation for his work on gene editing to defeat glioblastoma multiforme. His approach involves delivering gene therapy agents directly to tumor cells, aiming to improve survival and reduce side effects.
Researchers demonstrate a new way to deliver medication to malignant brain tumors in mice, using a modified peptide that can penetrate the blood-brain barrier. The study shows promising results, with a 50% increase in survival rate for treated mice, and offers hope for future treatment breakthroughs.
A new study successfully tested an implantable pump that delivers chemotherapy directly to the brain, bypassing the blood-brain barrier. The treatment effectively kills brain tumor cells and offers a safe way to treat patients with brain cancer.
Researchers developed a mouse model of pediatric glioma with a histone mutation called H3.3-G34, revealing a promising outlook for long-term survival through radiation therapy combined with small-molecule inhibitors. The treatment approach also showed immune memory, allowing mice to eliminate new tumor growth without additional treatment.
The DiaQNOS project aims to develop quantum sensors for improved brain tumor surgery. Magnetic field sensors will refine neuronavigation, enabling more precise incision paths. Researchers from Mainz University and partners will create a device suitable for use in surgery.
Researchers have discovered two novel drugs that can block the growth and shrink the size of schwannoma tumors, a type of nerve sheath tumor found in the nervous system. The treatment works by inhibiting the Hippo signaling pathway, which is dysregulated in multiple types of cancer.
Researchers found that reducing SAMHD1 levels made brain tumor cells sensitive to chemotherapy drugs and slowed cell growth. They also suspect that glioblastoma alters SAMHD1's function to aid its own survival and treatment resistance.
Scientists have uncovered the mechanics of the blood-tumour barrier in medulloblastoma, a malignant paediatric brain tumour. By silencing a specific ion channel, researchers found that chemotherapy medication etoposide was better able to cross the barrier and treat the tumour cells.
A novel algorithm uses near-infrared spectroscopy to estimate intracranial pressure (ICP) based on hemoglobin levels. The research validates the accuracy of this method using invasive ICP data.
WayPath Pharma has been awarded a $225,000 Phase I Small Business Technology Transfer (STTR) award to develop new metabolic drugs targeting tumor stem cells and crossing the blood-brain barrier. The funding aims to advance treatment options for glioblastoma, a highly aggressive brain cancer with limited treatment options.
Researchers discovered that animal models with germline alteration rs55705857 developed gliomas significantly faster than those without the alteration. The study offers new insights into tumor formation and may lead to novel therapies targeting this specific change.
A new study has uncovered a previously unknown genetic process that could inform the development of novel treatment options for glioblastoma (GBM), a virtually incurable brain tumor. The epidermal growth factor receptor (EGFR) signaling pathway and long non-coding RNA molecules, such as lncEPAT, play critical roles in GBM tumorigenesis.